尘肺病合并肺结核诊断与治疗中国专家共识
尘肺病合并肺结核患病率和致残率高、早期诊断困难,是严重公共卫生问题。中华医学会结核病学分会与中国防痨协会职业卫生与职业病专业委员会组织呼吸、职业病、结核病等领域多学科专家制定本共识,总结12个关键临床问题并提出13条针对性推荐。共识已在国际实践指南注册平台注册(PREPARE-2024CN271),旨在提高临床早期诊断能力、规范诊治、改善患者结局,并为我国职业病与传染病防控提供实用指导。
要点
- 尘肺病患者出现不典型影像表现或常规治疗反应差时,应积极获取病理标本,联合抗酸染色、结核分枝杆菌培养或分子病理检测提高检出率(2C)。
- 尘肺病患者行胸部CT及动态随访时,应关注多灶性、多形性病变及提示活动性结核的短期影像变化(2C)。
- 疑似肺结核合并尘肺病者,痰细菌学检查可因粉尘干扰出现假阴性,推荐重复采样或联合支气管镜BALF细菌学与分子检测,并结合IGRA、TST综合判断(2B)。
- 尘肺病合并药物敏感肺结核采用标准一线四药抗结核方案,疗程一般≥6-8个月;病变严重或合并气管、胸膜、肺外结核者延长至≥9-12个月(2A)。
- 利福平为强效肝酶诱导剂,可加速糖皮质激素、尼达尼布等合用药代谢并降低疗效,启动或停用利福平时应相应调整受影响药物剂量(1B)。
适用人群与场景
- 尘肺病合并肺结核的患者,包括疑似肺结核合并尘肺病需鉴别诊断者。
- 尘肺病合并药物敏感肺结核需抗结核治疗者。
- 尘肺病合并肺结核同时接受尘肺病治疗(如粉防己碱、尼达尼布、吡非尼酮、糖皮质激素、支气管扩张剂等)者。
- 终末期尘肺病合并肺结核等待肺移植者。
- 严重终末期尘肺病合并肺结核且不再从积极治疗中获益者。
- 符合手术或介入治疗指征的尘肺病合并结核患者。
诊断标准与关键阈值
- 尘肺病合并肺结核诊断遵循综合诊断原则:患者分别符合尘肺病和肺结核国家诊断标准,结合职业暴露史、动态影像变化和实验室结果综合评估,并按结核活动性分层管理(2C)。
- 尘肺病合并肺结核与非结核分枝杆菌(NTM)肺病鉴别:NTM肺病常累及上叶尖段和前段、右中叶及左上叶舌段,典型影像为中心小叶结节合并支气管扩张;硅肺合并NTM肺病常见多发薄壁空洞;病理以 epithelioid 肉芽肿为主、干酪样坏死不明显;确诊依赖分枝杆菌培养和菌种鉴定,符合临床、影像和微生物学综合标准(2C)。
处置流程与药物剂量
- 尘肺病合并药物敏感肺结核:采用标准一线四药抗结核方案,保证足够疗程(一般≥6-8个月);病变严重或合并气管、胸膜或肺外结核者延长疗程至≥9-12个月,以改善临床结局、减少复发(2A)。
- 尘肺病合并肺结核患者同时接受尘肺病治疗(包括粉防己碱、尼达尼布、吡非尼酮、糖皮质激素、支气管扩张剂等)和含利福平抗结核方案时,应知悉利福平为强效肝酶诱导剂,可加速糖皮质激素、尼达尼布等合用药代谢并降低疗效;启动或停用利福平时应相应调整受影响药物剂量(1B)。
- 疑似尘肺病合并肺结核:痰细菌学检查可因粉尘干扰出现假阴性,推荐重复采样或联合检测方法,包括经支气管镜获取BALF进行细菌学和分子检测;同时结合IGRA、TST等免疫学检测结果综合判断;影像和临床症状不典型者优先行支气管镜引导下病理采样(如EBUS-GS、ENB),微生物学证据不足时建议经皮肺活检或胸膜活检(有胸腔积液者)以明确诊断(2B)。
- 疑似尘肺病合并肺曲霉病:行支气管镜采集BALF或组织标本做真菌培养和病理检查(金标准);行BALF半乳甘露聚糖(GM)试验、mNGS或其他DNA检测;检测血清烟曲霉特异性抗体(如IgE-m3、IgM)(1A)。
- 尘肺病合并肺结核抗结核治疗后出现空洞进行性增大或新发空洞伴症状加重时,影像科医师应评估肺曲霉病影像征象,如早期晕征和晚期空洞内空气新月征(2C)。
- 终末期尘肺病合并肺结核等待肺移植者,ECMO可作为桥接肺移植使用(2D)。
- 终末期尘肺病合并肺结核已接受充分规范抗结核治疗者,应评估肺移植可行性;移植前注意:确保活动性结核完全控制;优化抗结核方案(如以利福布汀替代利福平)以维持免疫抑制剂有效浓度(2D)。
- 严重终末期尘肺病合并肺结核不再从积极治疗中获益者,应启动姑息治疗和临终关怀;临床医师和医疗团队应与患者及家属充分沟通病情、预后、治疗选择和医疗负担,核心目标是缓解症状、减轻痛苦、提高生活质量(2D)。
红旗征与不能漏的情况
- 尘肺病患者抗结核治疗后出现空洞进行性增大或新发空洞伴症状加重,需警惕肺曲霉病,评估早期晕征和晚期空气新月征(2C)。
- 尘肺病患者出现不典型影像表现或对常规治疗反应差,应积极获取病理标本以确诊(2C)。
- 疑似肺结核合并尘肺病者痰细菌学检查可因粉尘干扰出现假阴性,需重复采样或联合支气管镜BALF检测,避免漏诊(2B)。
研究设计与关键结果
- 本共识由中华医学会结核病学分会与中国防痨协会职业卫生与职业病专业委员会组织多学科专家制定,总结12个关键临床问题并提出13条针对性推荐。
- 共识已在国际实践指南注册平台注册(PREPARE-2024CN271)。
证据类型、等级与局限
- 证据类型:专家共识;推荐条款标注证据等级(1A、1B、2A、2B、2C、2D)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 尘肺病患者胸部CT检查及动态随访时应关注多灶性、多形性病变及提示活动性结核的短期影像变化(2C)。
- 疑似肺结核合并尘肺病者,不应仅依赖痰细菌学检查,应重复采样或联合支气管镜BALF细菌学与分子检测,并结合IGRA、TST综合判断(2B)。
- 尘肺病合并药物敏感肺结核采用标准一线四药方案,疗程一般≥6-8个月,病变严重或合并气管、胸膜、肺外结核者延长至≥9-12个月(2A)。
- 合用含利福平方案时,应知悉利福平可加速糖皮质激素、尼达尼布等药物代谢并降低疗效,启动或停用利福平时调整受影响药物剂量(1B)。
- 终末期尘肺病合并肺结核等待肺移植者,ECMO可作为桥接肺移植使用(2D);已接受充分规范抗结核治疗者应评估肺移植可行性,移植前确保活动性结核完全控制并以利福布汀替代利福平维持免疫抑制剂有效浓度(2D)。
- 严重终末期患者不再从积极治疗中获益时,应启动姑息治疗和临终关怀,与患者及家属充分沟通病情、预后、治疗选择和医疗负担(2D)。
- 符合手术或介入指征者由多学科团队联合决策,充分评估肺功能、营养状况和手术风险后及时治疗;手术主要适用于耐药结核伴局限病变、持续排菌的持续空洞病变、毁损肺、内科治疗无效的大咯血、结核性脓胸等危重情况。
指南或共识出处
- Chinese expert consensus on the diagnosis and treatment of pneumoconiosis complicated with tuberculosis(尘肺病合并肺结核诊断与治疗中国专家共识),中华医学会结核病学分会、中国防痨协会职业卫生与职业病专业委员会。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Pneumoconiosis complicated with pulmonary tuberculosis is characterized by high prevalence and disability rates, as well as difficulty in early diagnosis, constituting a serious public health problem. The Chinese Society of Tuberculosis (Chinese Medical Association) and the Society of Labor Hygiene and Occupational Diseases (Chinese Preventive Medicine Association) organized multidisciplinary experts in respiratory diseases, occupational diseases, tuberculosis and other related fields to formulate the Chinese expert consensus on the diagnosis and treatment of pneumoconiosis complicated with tuberculosis. This consensus aims to enhance professional practitioners' understanding of the disease, improve the capacity for early clinical diagnosis, and further advance the prevention and treatment of pneumoconiosis complicated with pulmonary tuberculosis in China. It summarizes 12 key clinical issues and proposes 13 targeted recommendations to address difficulties and misconceptions in clinical practice. This consensus was registered on the International Practice Guidelines Registry Platform (PREPARE-2024CN271). It aims to enhance the standardized diagnosis and treatment of pneumoconiosis complicated by pulmonary tuberculosis, improve patient outcomes, and provide practical guidance for the prevention and control of occupational and infectious diseases in China. The main recommendations are as follows.Recommendation 1: Clinicians and pathologists are advised to pay attention to the mixed pathological features of pneumoconiosis complicated with pulmonary tuberculosis. For patients with pneumoconiosis presenting atypical imaging manifestations or poor response to conventional treatment, pathological specimens should be actively obtained to confirm the diagnosis. Combined use of acid-fast staining, Mycobacterium tuberculosis culture or molecular pathological detection is recommended to increase the detection rate (2C).Recommendation 2: When performing chest CT examinations and dynamic follow-up for pneumoconiosis patients, clinicians and radiologists should focus on multifocal and polymorphic lesions, as well as short-term imaging changes suggestive of active tuberculosis (2C).Recommendation 3: For patients with suspected pulmonary tuberculosis complicated with pneumoconiosis: (1) Be aware that sputum bacteriological tests may yield false-negative results due to dust interference. Repeated sampling or combined detection methods are recommended, including bacteriological and molecular tests on bronchoalveolar lavage fluid (BALF) obtained via bronchoscopy. Results of immunological assays such as the interferon-γ release assay (IGRA) and tuberculin skin test (TST)shall also be combined for comprehensive judgment. (2) In cases with atypical imaging findings and clinical symptoms, bronchoscopy-guided pathological sampling (e.g., EBUS-GS [endobronchial ultrasound with guide sheath], ENB [electromagnetic navigation bronchoscopy]) is prioritized. When microbiological evidence is insufficient, percutaneous lung biopsy or pleural biopsy (for patients with pleural effusion) is suggested to clarify the diagnosis (2B).Recommendation 4: The diagnosis of pneumoconiosis complicated with pulmonary tuberculosis shall follow the integrated diagnostic principle. Provided that patients meet the national diagnostic criteria for pneumoconiosis and pulmonary tuberculosis respectively, a comprehensive assessment shall be conducted combining occupational exposure history, dynamic imaging changes and laboratory results. Patients shall be stratified for managementaccording to the activity of tuberculosis (2C).Recommendation 5: For differential diagnosis between pneumoconiosis complicated with pulmonary tuberculosis and non-tuberculous mycobacterial (NTM) lung disease: (1) NTM lung disease commonly involves the apical and anterior segments of the upper lobes, the right middle lobe and the lingular segment of the left upper lobe. Typical imaging manifestations include a combination of centrilobular nodules and bronchiectasis. (2) Multiple thin-walled cavities are frequently seen in silicosis complicated with NTM lung disease. (3) Pathologically, NTM lesions are dominated by epithelioid granulomas with inconspicuous caseous necrosis. (4) Definitive diagnosis relies on mycobacterial culture and species identification, complying with combined clinical, imaging and microbiological criteria (2C).Recommendation 6: For patients with pneumoconiosis complicated with pulmonary tuberculosis who present progressively enlarged cavities or newly developed cavities accompanied by aggravated symptoms after anti-tuberculosis treatment, radiologists shall evaluate imaging signs of pulmonary aspergillosis, such as the early halo sign and the late air crescent sign within cavities (2C).Recommendation 7: For patients with suspected pneumoconiosis complicated with pulmonary aspergillosis: (1) Bronchoscopy is performed to collect BALF or tissue specimens for fungal culture and pathological examination (gold standard). (2) Conduct BALF galactomannan (GM) test, metagenomic next-generation sequencing (mNGS) or other DNA detection assays. (3) Detect serum specific antibodies against Aspergillus fumigatus (e.g., IgE-m3, IgM) (1A).Recommendation 8: For patients with pneumoconiosis complicated with drug-susceptible pulmonary tuberculosis: (1) Adopt the standard first-line four-drug anti-tuberculosis regimen. (2) Ensure a sufficient treatment course (generally ≥6-8 months). (3) Extend the treatment course to≥9-12 months for patients with severe lesions or concomitant tracheal, pleural or extrapulmonary tuberculosis, so as to improve clinical outcomes and reduce recurrence (2A).Recommendation 9: For patients receiving concurrent treatment for pneumoconiosis (including tetrandrine, nintedanib, pirfenidone, glucocorticoids, bronchodilators, etc.) and rifampicin-containing anti-tuberculosis regimens: (1) Be aware that rifampicin, a potent hepatic enzyme inducer, may accelerate the metabolism of concomitant drugs such as glucocorticoids and nintedanib and reduce their efficacy. (2) Adjust the dose of affected drugs accordingly when rifampicin is initiated or discontinued (1B).Recommendation 10: Extracorporeal membrane oxygenation (ECMO) may be used as a bridge to lung transplantation only for end-stage pneumoconiosis patients complicated with pulmonary tuberculosis awaiting transplantation (2D).Recommendation 11: For end-stage patients with pneumoconiosis complicated with pulmonary tuberculosis who have received adequate and standard anti-tuberculosis therapy, the feasibility of lung transplantation shall be evaluated. Pre-transplant precautions: (1) Ensure complete control of active tuberculosis. (2) Optimize the anti-tuberculosis regimen (e.g., replace rifampicin with rifabutin) to maintain the effective concentration of immunosuppressants (2D).Recommendation 12: For patients with severe, end-stage pneumoconiosis complicated with pulmonary tuberculosis who no longer benefit from active treatment, palliative care and hospice care shall be initiated. Clinicians and medical teams shall communicate fully with patients and their families about the condition, prognosis, treatment options and medical burden. The core goals are to relieve symptoms, alleviate suffering and improve quality of life (2D).Recommendation 13: For patients with pneumoconiosis complicated with tuberculosis who meet the indications for surgical or interventional therapy, a multidisciplinary team shall conduct joint decision-making and implement treatment in a timely manner after full assessment of pulmonary function, nutritional status and surgical risks. Surgical treatment is mainly indicated for patients with drug-resistant tuberculosis with localized lesions, persistent cavitary lesions with ongoing mycobacterial excretion, destroyed lung, massive hemoptysis unresponsive to medical treatment, tuberculous empyema and other critical conditions. Interventional therapy can be applied for emergency treatment of massive hemoptysis, as well as palliative treatment for pulmonary artery stenosis secondary to tuberculosis or pneumoconiosis (2C).
尘肺病合并肺结核的患病率和致残率高、早期诊断困难,是严重的公共卫生健康问题。中华医学会结核病学分会、中华预防医学会劳动卫生与职业病分会组织呼吸病、职业病、结核病等相关领域多学科专家共同制订《尘肺病合并肺结核诊治中国专家共识》,旨在提升相关专业人员对该病的认识,提高临床早期诊断水平,从而推动我国尘肺病合并肺结核防治工作取得更大成效。共识共凝练出12个关键临床问题,并提出13项针对性推荐意见,旨在解决临床实践中的难点与误区。本共识旨在提升临床医生对尘肺病合并肺结核的规范化诊治水平,改善患者预后,为我国职业病与传染病防控提供实践指导。.
参考来源
- [Chinese expert consensus on the diagnosis and treatment of pneumoconiosis complicated with tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42557068. doi:10.3760/cma.j.cn112147-20260512-00273
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。